Sector News

ConvaTec to bolster senior leadership

December 5, 2017
Life sciences

Medical product and technology company ConvaTec Group PLC said on Monday it has made several senior appointments as a result of changes to its organisational structure.

From January 1, 2018 the group’s four franchises will he headed by Franchise Presidents who will report directly to the Chief Executive Officer, and will responsible for the development and delivery of its strategic plans across all its target markets, as well as marketing and research & development within their franchises.

Peter Byloos will be appointed as head of Advanced Wound Care. He will be joining from European investment company Gimv, where he is partner for healthcare for nearly three years since the start of 2015.

Erik Zimmer will continue as vice president & general manager of Ostomy Care, with an appointment of a president for the franchise to be made in due course.

ConvaTec will promote current Interim President of Europe, Middle East & Africa Frank Gehres as president of Continence and Critical Care, with Mads Haugaard reporting to him as vice president & general manager.

Gehres will be replaced as president of Europe, Middle East & Africa by Kjersti Grimsrud, who will be joining from rapid point-of-care diagnostics tests manufacturer Alere Inc, where she was president of Europe & Middle East and president International for three and a half years since 2014.

John Lindskog will continue as president with responsibility over the Infusion Devices franchise.

In addition, ConvaTec will appoint Sean McGrath as executive vice president of global human resources, joining from the World Bank Group where he was vice president of human resources for five years since 2012. He will be replacing Marc Reuss, who has held the role for two years since 2015.

Also, President of Global Franchises and Innovation Symeria Hudson, will be leaving with effect at the end of 2017, after nearly two years in the role since March 2016.

“These important changes to our organisation will drive a greater focus on the leadership of our Franchises and on their performance as business units of ConvaTec, as well as providing better leverage of our strong new product pipeline. I am confident that this new structure will enable us to drive increased value from our leading market positions across each of the businesses,” said Chief Executive Officer Paul Moraviec.

Shares in ConvaTec were up 1.2% at 201.90 pence on Monday.

By Dayo Laniyan

Source: Alliance News

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend